Fresenius Medical Care Corporation, also known as FMS, is a leading company that specializes in providing life-saving dialysis services and products. The company's operations and offerings cut across both the chronic and acute treatments of kidney disease and its associated conditions. The company is widely recognized for its innovative contributions to the health sector, especially in the niche of dialysis.
FMS was established in 1996 after Fresenius, a health care group based in Germany, merged with National Medical Care (an American company). The company operates on a truly global scale, with more than 3,500 dialysis clinics in over 120 countries worldwide. It also has production plants in more than 10 countries that produce dialysis devices and related disposables.
FMS's core competencies include providing both inpatient and outpatient dialysis services and also taking part in critical research for the improvement of kidney failure treatments. The company’s dialysis services provide life-sustaining treatments to around 350,000 patients worldwide, aiming to improve their quality of life and manage kidney diseases better.
FMS is also committed to creating innovative devices and breakthrough therapies. The company’s products range from dialysis machines and dialyzers to bloodlines, concentrates, and pharmaceuticals. These have been instrumental in advancing peritoneal dialysis, a home-based treatment where patients can dialyze in the comfort of their own homes.
Furthermore, FMS has engineered innovative technological solutions to increase the accessibility of treatment for those with kidney disease. A significant example of this is the 2008K hemodialysis machine which revolutionized the way the treatment is delivered. It offers increased personalization of therapy, ensuring better patient-monitoring, compliance, and improved treatment outcomes.
With its robust profile and strong leadership in the dialysis market, Fresenius Medical Care Corporation continues to make impact in the global health care environment, more specifically the fight against kidney disease. Its continued focus on integrating world-class medical care with cutting-edge technology further establishes its position as a global leader in dialysis therapy and related care services. This also validates FMS’s mission of delivering superior medical services to improve patients' quality of life.
In addition, FMS provides other support services such as laboratory diagnostics which help physicians to detect, treat, and manage diseases. They also offer renal medications to ensure coordinated and comprehensive care for patients.
Above all, Fresenius Medical Care is firmly committed to healthcare excellence, technological innovation, and optimal patient care. This commitment has positioned the company as a global leader in the fight against kidney disease, thus offering hope and improved quality of life for millions of people around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Fresenius Medical Care (FMS) announced a refined commercial strategy for China, which includes plans to exit its peritoneal dialysis business in the country. The article suggests that more details are available to premium subscribers, indicating a strategic shift for the company in the Chinese market.
Eleven ratings firms have given Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) a "Reduce" recommendation, with an average 12-month price target of $23.57. Despite this cautious sentiment, the company reported stronger-than-expected quarterly results, with adjusted earnings of $0.66 per share and revenue of $5.55 billion. Institutional ownership of FMS stock has increased, although collective institutional holdings remain at 8.37%.
The FDA issued a warning letter to Fresenius USA Manufacturing after finding major Current Good Manufacturing Practice violations at its Ogden, Utah facility. The company failed to adequately investigate customer complaints about leaking dialysis bags and had deficiencies in its visual inspection programs for sterile products. The FDA has advised Fresenius to hire an independent expert for an audit and warned of potential enforcement actions if compliance failures are not addressed.
The article summarizes analyst ratings for Fresenius Medical Care (FME) stock in August 2026. A majority of analysts recommend selling the stock, with 7 advising a sell, 5 a hold, and only 1 a buy. The average price target is €37.17, indicating a potential downside of -5.56%.
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has received a consensus "Reduce" rating from eleven brokerages, with an average 12-month price target of $23.57, which is close to its current price of $23.07. Despite mixed analyst actions including an upgrade by Bernstein and a downgrade by BNP Paribas Exane, the company surpassed quarterly expectations with $0.66 EPS and $5.55 billion in revenue. Institutional investors hold 8.37% of the stock, with several major funds increasing their positions.
The Fresenius Medical Care (FMC) St. stock recently experienced a "GD 100 crossed downwards" chart signal on August 31, 2026, indicating a down signal. The stock was trading down 0.2 percent at 39.38 EUR in XETRA. Fresenius Medical Care AG & Co. KGaA is a leading global provider of products and services for dialysis technology, treating chronic kidney failure.